# Candel Therapeutics, Inc.: filings

CADL · Nasdaq · CIK 1841387 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cadl.md) · [Financials](/companies/cadl/financials.md) · [Filings](/companies/cadl/filings.md) · [Insiders](/companies/cadl/insiders.md)

## Reports and events: 119 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 169, 8-K 85, 144 36, 3 25, 10-Q 16, CORRESP 9, 424B5 7, S-8 6, UPLOAD 6, 10-K 5, DEF 14A 5, ARS 4, SCHEDULE 13G 4, SCHEDULE 13G/A 4, 4/A 3, DEFA14A 3, EFFECT 3, S-1/A 3, SC 13G 3, 10-K/A 2, 5 2, S-3 2, 424B4 1, 5/A 1, 8-A12B 1, CERT 1, DRS 1, DRS/A 1, DRSLTR 1, S-1 1, SC 13D 1, SC 13G/A 1, SCHEDULE 13D/A 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-10 | 12:16 ET | [8-K](/filings/0001193125-26-387310.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-387310 |
| 2026-09-09 | 20:50 ET | [8-K](/filings/0001193125-26-386561.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-386561 |
| 2026-08-13 | 12:30 ET | [10-Q](/filings/0001193125-26-347980.md) | Quarterly report, period 2026-06-30 | 0001193125-26-347980 |
| 2026-08-13 | 12:15 ET | [8-K](/filings/0001193125-26-347957.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-347957 |
| 2026-06-24 | 20:24 ET | [8-K](/filings/0001841387-26-000009.md) | 5.07 Shareholder vote results | 0001841387-26-000009 |
| 2026-06-16 | 20:23 ET | [8-K](/filings/0001841387-26-000007.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001841387-26-000007 |
| 2026-05-15 | 20:13 ET | [8-K](/filings/0001193125-26-226751.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-226751 |
| 2026-05-14 | 12:30 ET | [10-Q](/filings/0001193125-26-222904.md) | Quarterly report, period 2026-03-31 | 0001193125-26-222904 |
| 2026-05-14 | 12:15 ET | [8-K](/filings/0001193125-26-222892.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-222892 |
| 2026-04-29 | 20:05 ET | [DEF 14A](/filings/0001193125-26-191506.md) | Proxy statement, period 2026-06-23 | 0001193125-26-191506 |
| 2026-03-18 | 20:23 ET | [SCHEDULE 13D/A](/filings/0001494695-26-000005.md) | Ownership report, active investor, amended | 0001494695-26-000005 |
| 2026-03-12 | 12:17 ET | [10-K](/filings/0001193125-26-103134.md) | Annual report, period 2025-12-31 | 0001193125-26-103134 |
| 2026-03-12 | 12:10 ET | [8-K](/filings/0001193125-26-103126.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-103126 |
| 2026-02-23 | 13:00 ET | [8-K](/filings/0001193125-26-062490.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-062490 |
| 2026-02-19 | 21:03 ET | [8-K](/filings/0001193125-26-059334.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-059334 |
| 2025-12-05 | 13:30 ET | [8-K](/filings/0001193125-25-308719.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-308719 |
| 2025-11-13 | 13:30 ET | [10-Q](/filings/0001193125-25-279086.md) | Quarterly report, period 2025-09-30 | 0001193125-25-279086 |
| 2025-11-13 | 13:15 ET | [8-K](/filings/0001193125-25-279072.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-279072 |
| 2025-10-14 | 12:21 ET | [8-K](/filings/0001193125-25-238254.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-238254 |
| 2025-08-21 | 20:30 ET | [8-K](/filings/0000950170-25-110682.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0000950170-25-110682 |
| 2025-08-14 | 12:10 ET | [10-Q](/filings/0000950170-25-108450.md) | Quarterly report, period 2025-06-30 | 0000950170-25-108450 |
| 2025-08-14 | 12:07 ET | [8-K](/filings/0000950170-25-108448.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-108448 |
| 2025-06-24 | 13:27 ET | [8-K](/filings/0001193125-25-145405.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-145405 |
| 2025-06-23 | 12:15 ET | [8-K](/filings/0001193125-25-144204.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-144204 |
| 2025-06-18 | 12:30 ET | [8-K](/filings/0000950170-25-087696.md) | 5.07 Shareholder vote results | 0000950170-25-087696 |
| 2025-06-06 | 12:11 ET | [8-K](/filings/0000950170-25-082705.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-082705 |
| 2025-05-28 | 12:10 ET | [8-K](/filings/0000950170-25-078079.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-078079 |
| 2025-05-22 | 21:12 ET | [8-K](/filings/0000950170-25-076458.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-076458 |
| 2025-05-13 | 12:30 ET | [10-Q](/filings/0000950170-25-069833.md) | Quarterly report, period 2025-03-31 | 0000950170-25-069833 |
| 2025-05-13 | 12:15 ET | [8-K](/filings/0000950170-25-069826.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-069826 |
| 2025-04-29 | 20:05 ET | [DEF 14A](/filings/0000950170-25-060093.md) | Proxy statement, period 2025-06-17 | 0000950170-25-060093 |
| 2025-04-23 | 20:15 ET | [8-K](/filings/0000950170-25-057398.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-057398 |
| 2025-03-27 | 01:57 ET | [8-K](/filings/0001193125-25-064374.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-064374 |
| 2025-03-13 | 20:30 ET | [10-K](/filings/0000950170-25-038803.md) | Annual report, period 2024-12-31 | 0000950170-25-038803 |
| 2025-03-13 | 20:15 ET | [8-K](/filings/0000950170-25-038757.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-038757 |
| 2025-02-25 | 13:15 ET | [8-K](/filings/0000950170-25-026100.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-026100 |
| 2025-01-13 | 13:05 ET | [8-K](/filings/0000950170-25-004581.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-004581 |
| 2024-12-13 | 22:30 ET | [8-K](/filings/0001193125-24-278717.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-278717 |
| 2024-12-11 | 12:45 ET | [8-K](/filings/0001193125-24-274870.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-274870 |
| 2024-11-14 | 13:30 ET | [10-Q](/filings/0000950170-24-126767.md) | Quarterly report, period 2024-09-30 | 0000950170-24-126767 |
| 2024-11-14 | 13:15 ET | [8-K](/filings/0000950170-24-126759.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-126759 |
| 2024-10-28 | 12:30 ET | [8-K](/filings/0000950170-24-117578.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-117578 |
| 2024-08-13 | 12:30 ET | [10-Q](/filings/0000950170-24-095784.md) | Quarterly report, period 2024-06-30 | 0000950170-24-095784 |
| 2024-08-13 | 12:15 ET | [8-K](/filings/0000950170-24-095775.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-095775 |
| 2024-06-28 | 12:39 ET | [8-K](/filings/0000950170-24-078795.md) | 5.07 Shareholder vote results | 0000950170-24-078795 |
| 2024-05-30 | 20:30 ET | [DEF 14A](/filings/0001193125-24-150379.md) | Proxy statement, period 2024-06-26 | 0001193125-24-150379 |
| 2024-05-30 | 20:15 ET | [8-K](/filings/0000950170-24-066608.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0000950170-24-066608 |
| 2024-05-23 | 21:05 ET | [8-K](/filings/0000950170-24-064022.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-064022 |
| 2024-05-14 | 12:30 ET | [10-Q](/filings/0000950170-24-059118.md) | Quarterly report, period 2024-03-31 | 0000950170-24-059118 |
| 2024-05-14 | 12:15 ET | [8-K](/filings/0000950170-24-059109.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-059109 |

Page 1 of 3. [Older](/companies/cadl/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:15 ET. No prices; not investment advice.